Anti-LAG-3 boosts CD8 T cell effector function.
Where this comes from
- Record sourced from PubMed, PMID 39121844.
- Also identified by DOI 10.1016/j.cell.2024.07.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.
Medical subject headings
- Lymphocyte Activation Gene 3 Protein
- CD8-Positive T-Lymphocytes
- Antigens, CD